TRAb measurements may be useful in following:

·      Diagnosis of clinically suspected Graves’ disease

·      Assessment of the neonatal thyrotoxicosis risk in a fetus of female with Graves’ disease (active or treated)

·      Diagnosis of gestational thyrotoxicosis / recurrent Graves’ disease / normal first trimester of pregnancy

·      Graves’ disease relapse in treated patient

·      Differential diagnosis of thyrotoxicosis in patients with unclear biochemical findings or pregnancy.

Patient preparation instructions: Avoid high biotin doses (i.e. > 300 mg/day) for three days prior to specimen collection.

Interpretation: Results ³1.8 IU/L have sensitivity of 97% and specificity of 99% for Graves’ disease.

Method of Analysis: Roche Electrochemiluminescence